Human Metabolome Technologies Market capitalization 2024

The Human Metabolome Technologies Market capitalization history

YEAR	REVENUE (undefined JPY)	GROSS MARGIN (%)	NET INCOME (undefined JPY)
2026e	1.48	58,13	270.33
2025e	1.46	59,05	232.83
2024e	1.41	60,80	202.54
2023	1.3	66,17	285.76
2022	1.22	68,67	267.79
2021	1.12	71,71	58.21
2020	1.12	76,60	-47.79
2019	0.99	67,99	-596.03
2018	0.94	79,14	-156.53
2017	0.91	79,75	-61.91
2016	0.78	73,13	-71.47
2015	0.69	67,89	-34.73
2014	0.61	67,50	1.6
2013	0.5	59,24	-95.3
2012	0.52	70,63	-46.4
2011	0.57	71,28	75.4
2010	0.38	67,45	-39.8
2009	0.25	59,88	-275.3

Human Metabolome Technologies Aktienanalyse

What does Human Metabolome Technologies do?

Human Metabolome Technologies Inc (HMT) is a Japanese company specializing in the research and development of metabolome analysis. HMT was founded in 2000 with the vision of gaining a deeper understanding of the metabolic processes of the human body in order to contribute to better healthcare. HMT's business model involves conducting metabolome analysis using mass spectrometry and other technologies to characterize the body's metabolic processes. This includes analyzing both healthy and diseased metabolism from samples such as blood, urine, or tissue in large numbers to identify biomarkers or signatures that can be used in the early detection, diagnosis, prognosis, and treatment of diseases. In this sense, HMT serves as an important partner for researchers in the pharmaceutical and biomedical industry who want to develop new diagnostic and therapeutic approaches. In recent years, HMT has developed a wide range of metabolome analysis technologies tailored to various applications. One of HMT's most important products is the Targeted Metabolomics Platform, which allows for the quantification of a variety of metabolites in samples such as blood or urine. This is an important step towards developing biomarkers that can serve as indicators of an organism's metabolic state. Another important platform of HMT is the Biomarker Discovery Platform, which specializes in the identification of biomarkers associated with specific diseases. This platform is often used by pharmaceutical companies to develop new drugs tailored to the specific needs of patients with certain diseases. HMT has also developed a comprehensive metabolome database that allows researchers and analysts to compare their own data with a variety of reference data. This database contains information on thousands of metabolites and allows researchers to better understand metabolic pathways and biomolecular interactions. In recent years, HMT has also increased its investment in clinical research to explore the potentials of metabolome analysis in the diagnosis and treatment of cancer, diabetes, cardiovascular diseases, metabolic disorders, and other diseases. In collaboration with clinics and universities, HMT has conducted several clinical studies to evaluate the effectiveness of metabolome analysis in the early detection and monitoring of diseases. HMT is headquartered in Tsuruoka, Japan, and is also active in the US, Europe, and Asia. The company employs over 100 people and has become a leading provider of metabolome analysis and services. In summary, HMT has developed unique expertise in the field of metabolome analysis and is able to offer a wide range of products and services to support researchers and analysts in the study of the metabolic processes of the human body. With a strong emphasis on innovation and clinical research, HMT will continue to play an important role in the development of new diagnostic and therapeutic approaches tailored to the specific needs of patients. Human Metabolome Technologies ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Market capitalization Details

Exploring Human Metabolome Technologies's Market Capitalization

Human Metabolome Technologies's market capitalization represents the total dollar market value of the company’s outstanding shares of stock. It is calculated by multiplying the company's shares outstanding by the current market price of one share. This metric is a vital indicator of a company’s size, strength, and overall market value.

Year-to-Year Comparison

A yearly comparison of Human Metabolome Technologies's market capitalization provides investors and analysts insights into its growth and valuation trends. An increase signifies market confidence and business expansion, while a decrease may point towards declining market value or business contractions.

Impact on Investments

Human Metabolome Technologies's market capitalization plays a pivotal role in investment decisions. It aids investors in assessing the company's risk and return profiles. Larger companies are often considered more stable but may offer lower growth potential, while smaller companies might offer significant growth prospects but come with higher risk.

Interpreting Market Capitalization Fluctuations

Variations in Human Metabolome Technologies’s market capitalization can be attributed to several factors, including changes in stock price, outstanding shares, and market sentiment. Understanding these fluctuations helps investors evaluate the company's current standing and future potential in the competitive landscape.

Frequently Asked Questions about Human Metabolome Technologies Stock

What is the current Human Metabolome Technologies market capitalization?

The current market capitalization of Human Metabolome Technologies is 3.8 B JPY.

What is market capitalization?

The market capitalization (German: Marktkapitalisierung, English: market capitalization, abbreviated as market cap, also known as stock exchange capitalization or market value) is the calculated total value of all shares of a publicly traded company like Human Metabolome Technologies.

How has the market capitalization of Human Metabolome Technologies developed in recent years?

The market capitalization of Human Metabolome Technologies has increased/decreased by -14.86% compared to the previous year.

What does market capitalization mean for investors?

The market capitalization of a company reflects the current market consensus on the value of the equity of a publicly traded company.

Why is market capitalization an important indicator for investors?

The market capitalization of a company reflects the current market consensus on the value of a publicly traded company's equity. It is determined by the supply and demand for the company's shares. Market capitalization is thus significantly influenced by expectations in the stock market regarding the future earnings power of the company, and as such, it can undergo significant fluctuations.

Why does the market capitalization fluctuate?

The market capitalization fluctuates along with the stock price, as the market capitalization is calculated based on the current price and the number of outstanding shares.

What role does market capitalization play in the valuation of Human Metabolome Technologies?

In order to compare the value of companies, it is helpful to consider not only the market capitalization but also the net debt of a company. A potential buyer of the entire company would also acquire the debts of the company. The enterprise value is the total value of a company or a stock corporation. The net financial indebtedness of the company is added to the market capitalization.

Does the market capitalization influence the performance of Human Metabolome Technologies?

There is no verifiable long-term evidence or study that stocks with a specific market capitalization (whether Mega/Large/Mid/Small Cap) would consistently yield significantly higher returns than others. There are occasional small studies (few stocks, short investment period) suggesting that certain classes may perform better or have higher risk, but none of them are 1. conclusive (cause-effect relationship is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

Does the market capitalization of Human Metabolome Technologies have an influence on indices?

Some stock indices use market capitalization as index weighting. Stocks with a higher market capitalization are also weighted higher in the index. This is in contrast to equally weighted indices (all stocks have the same weighting) and free float weighted indices (market capitalization weighting, but only with the number of shares in free float).

How much dividend does Human Metabolome Technologies pay?

Over the past 12 months, Human Metabolome Technologies paid a dividend of 10 JPY . This corresponds to a dividend yield of about 1.56 %. For the coming 12 months, Human Metabolome Technologies is expected to pay a dividend of 10 JPY.

What is the dividend yield of Human Metabolome Technologies?

The current dividend yield of Human Metabolome Technologies is 1.56 %.

When does Human Metabolome Technologies pay dividends?

Human Metabolome Technologies pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Human Metabolome Technologies?

Human Metabolome Technologies paid dividends every year for the past 0 years.

What is the dividend of Human Metabolome Technologies?

For the upcoming 12 months, dividends amounting to 10 JPY are expected. This corresponds to a dividend yield of 1.56 %.

In which sector is Human Metabolome Technologies located?

Human Metabolome Technologies is assigned to the 'Health' sector.

Wann musste ich die Aktien von Human Metabolome Technologies kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Human Metabolome Technologies from 9/1/2024 amounting to 15 JPY, you needed to have the stock in your portfolio before the ex-date on 6/27/2024.

When did Human Metabolome Technologies pay the last dividend?

The last dividend was paid out on 9/1/2024.

What was the dividend of Human Metabolome Technologies in the year 2023?

In the year 2023, Human Metabolome Technologies distributed 0 JPY as dividends.

In which currency does Human Metabolome Technologies pay out the dividend?

The dividends of Human Metabolome Technologies are distributed in JPY.